^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/28/2017
Excerpt:
Besponsa is indicated as monotherapy...Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).
Source:
Published date:
04/09/2021
Excerpt:
Regimens for relapsed or refractory Ph-positive B-ALL...Other recommended regimens…Inotuzumab ozogamicin ± bosutinib (for B-ALL)
Source:
Published date:
04/09/2021
Excerpt:
Regimens for relapsed or refractory Ph-positive B-ALL...Other recommended regimens…Inotuzumab ozogamicin ± bosutinib (for B-ALL)
Secondary therapy:
bosutinib
Source:
Title:
1411 A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
Published date:
11/03/2022
Excerpt:
At a median follow up of 18 months (mos) (range, 1.1- 35 mos), 14 of the 18-responding pts (78%) are in ongoing MRD-ve CR. The median RFS and OS of the pts were not reached. The estimated 18-mos RFS and OS were 56% and 65%, respectively, for the whole group. 18-mos OS was 73% and 60% for responders and non-responders, respectively (p=0.7)...Survival was similar between pts with Ph+ ALL vs. Ph- ALL (p=0.41), pts in CR1 vs. ≥ CR2 (p=0.23) and those with prior blinatumomab exposure vs. no prior exposure (p=40). Lower doses of fractionated INO is a well-tolerated option for MRD eradication in pts with Ph+ or Ph- B-ALL, including in those with prior blinatumomab exposure or SCT.
DOI:
https://doi.org/10.1182/blood-2022-170667
Source:
Title:
A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Published date:
05/12/2022
Excerpt:
In the Ph+ group, 6 pts (50%) responded; another 3 pts attained MMR as best response. Low-dose, fractionated INO is a well-tolerated option for MRD eradication in Ph+ and Ph- B-ALL pts, including in those with prior blina exposure.
